CD19 and neoplasm: In addition, more ADGRE1 RNA molecules were detected in IMSA101-treated tumors (Fig. 5g), while RNA-count of the tumor antigens, mouse mesothelin or human CD19, was lower in these cohorts consistent with anti-tumor response (Supplementary Fig. 11e).